1.
Mueser KT, McGurk SR. Schizophrenia. Lancet 2004; 363 : 2063–71.
2.
Jablensky A. The 100-year epidemiology of schizophrenia. Schizophr Res 1997; 28 : 111–25.
3.
Murray RM, Van Os J. Predictors of outcome in schizophrenia. J Clin Psychopharmacol 1998; 18 : S2–4.
4.
Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 2006; 32 : 200–2.
5.
Torrey EF, Yolken RH. Toxoplasma gondii and schizophrenia. Emerg Infect Dis 2003; 9 : 1375–80.
6.
Inskip HM, Harris EC, Barraclough C. Lifetime risk of suicide for alcoholism, affective disorder and schizophrenia. Br J Psychiatry 1998; 172 : 35–7.
7.
Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol o other drug abuse : results from the epidemiologic catchment area (ECA) study. JAMA 1990; 264 : 2511–8.
8.
Maier W, Lichtermann D, Franke P, et al. The dichotomy of schizophrenia and affective disorders in extended pedigrees. Schizophr Res 2002; 57 : 259–66.
9.
Tsuang M. Schizophrenia : genes and environment. Biol Psychiatry 2000;47 : 210–20.
10.
Craddock N, O’Donovan MC, Owen MJ. The genetics of schizophrenia and bipolar disorder : dissecting psychosis. J Med Genet 2005; 42 : 193–204.
11.
Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait : evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003; 60 : 1187–92.
12.
McGrath JJ, Susser ES. New directions in the epidemiology of schizophrenia. Med J Aust 2009; 16 ; 190 : S7–9.
13.
Brown AS, Cohen P, Harkavy-Friedman J, et al. AE Bennett research Award : prenatal rubella, premorbid abnormalities, and adult schizophrenia. Biol Psychiatry 2001; 49 : 473–86.
14.
Brown AS, Begg MD, Gravenstein S, et al. Serologic evidence for prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004;61 : 774–80.
15.
Buka SL, Cannon TD, Torrey EF, Yolken RH. Collaborative study group on the perinatal origins of severe psychiatric disorders. Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biol Psychiatry 2008; 63 : 809–15.
16.
Fellerhoff B, Laumbacher B, Wank R. High risk of schizophrenia and other mental disorders associated with chlamydial infections : hypothesis to combine drug treatment and adoptive immunotherapy. Med Hypotheses 2005; 65 : 243–52.
17.
Brown AS, Schaefer CA, Quesenberry CP, et al. Maternal Exposure to Toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry 2005; 162 : 4.
18.
Torrey EF, Bartko JJ, Lun ZR, Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia : a meta-analysis. Schizophr Bull 2007;33 : 729–36.
19.
Ledgrewood LG, Ewald PW, Cochan GM. Genes, germs, and schizophrenia : an evolutionary perspective. Perspect Biol Med 2003; 46 : 317–48.
20.
Grigg ME, Bonnefoy S, Hehl AB, et al. Success and virulence in Toxoplasma as the result of sexual recombination between two distinct ancestries. Science 2001; 294 : 161–5.
21.
Wang HL, Wang GH, Li QY, et al. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr Scand 2006; 114 : 40–8.
22.
Amminger GP, McGorry PD, Berger GE, et al. Antibodies to infectious agents in individuals at ultra-high risk for psychosis. Biol Psychiatry 2007; 61 : 1215–7.
23.
Niebuhr DW, Millikan AM, Cowan DN, et al. Selected infectious agents and risk of schizophrenia among U.S. military personnel. Am J Psychiatry 2008; 165 : 99–106.
24.
Johnson JJ, Roberts CW, Pope C, et al. In vitro correlates of Ld-restricted resistance to toxoplasmic encephalitis and their critical dependence on parasite strain. J Immunol 2002; 169 : 966–73.
25.
Mortensen PB, Nørgaard-Pedersen B, Waltoft BL, et al. Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophr Bull 2007; 33 : 741–4.
26.
Grimwood B, O’Connor G, Gaafar HA. Toxofactor associated with Toxoplasma gondii infection is toxic and teratogenic to mice. Infect Immun 1983; 42 : 1126–35.
27.
Wastling J, Heap S, Ferguson D. Toxoplasma gondii: keeping our guests under control. Biologist (London) 2000; 47 : 234–8.
28.
Webster JP, Brunton CF, MacDonald DW. Effects of Toxoplasma gondii upon neophobia behaviour in wild brown rats Rattus norvegicus. Parasitology 1994; 109 : 37–43.
29.
Vyas A, Kim SK, Giacomini N, et al. Bahavioral changes induced by Toxoplasma infection of rodents are highly specific to aversion of cat odors. Proc Natl Acad Sci USA 2007;104 : 6442–7.
30.
Flegr J, Zitkova S, Kodyn P, Frynta D. Induction of changes in human behavior by the parasitic protozoan Toxoplasma gondii. Parasitology 1996; 31 : 305–9.
31.
Flegr J, Preiss M, Klose J, et al. Decreased level of psychobiological factor novelty seeking and lower intelligence in men latently infected with the protozoan parasite Toxoplasma gondii dopamine, a missing link between schizophrenia and toxoplasmosis ? Biol Psychol 2003;63 : 253–68.
32.
Havlicek J, Gasova Z, Smith AP, et al. Decrease of psychomotor performance in subjects with latent asymptomatic toxoplasmosis. Parasitology 2001; 122 : 515–20.
33.
Minto A, Roberts FJ. The psychiatric complications of toxoplasmosis. Lancet 1959; 1 : 1180–2.
34.
Kramer W. Frontiers of neurological diagnosis in acquired toxoplasmosis. Psychiatr Neurol Neurochir 1966; 69 : 43–64.
35.
Stibbs HH. Changes in brain concentrations of catecholamines and indoleamines in Toxoplasma gondii infected mice. Ann Trop Med Parasitol 1985; 79 : 153–7.
36.
Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone : receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003; 64 : 6–12.
37.
Linnér L, Wiker C, Wadenberg ML, et al. Noradrenaline reuptake inhibition enhances the antipsychotic-like effect of raclopride and potentiates D2-blockage-induced dopamine release in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2002;27 : 691–8.
38.
Schwarcz R, Hunter CA. Toxoplasma gondii and schizophrenia: linkage through astrocyte-derived kynurenic acid ? Schizophr Bull 2007; 33 : 652–3.
39.
Schwarcz R, Rassoulpour A, Wu HQ, et al. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50 : 521–30.
40.
Martin LF, Kem WR Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) 2004; 174 : 54–64.
41.
Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006; 26 : 365–84.
42.
Adamec RE, Burton P, Shallow T, Budgell J. NMDA receptors mediate lasting increases in anxiety-like behaviour produced by the stress of predator exposure, implications for anxiety associated with post-traumatic stress disorder. Physiol Behav 1999; 65 : 723–37.
43.
Ellison-Wright I, Glahn DC, Laird AR, et al. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. Am J Psychiatry 2008; 165 : 1015–23.
44.
Krebs MO. Intégrité chromosomique et schizophrenie. Med Sci (Paris) 2009; 25 : 219–21.
45.
Buzoni-Gatel D, Dubremetz JF, Werts C. Manipulation du système immunitaire par le parasite Toxoplasma gondii. Med Sci (Paris) 2008; 24 : 191–6.